文献速递中毒与环境急症儿科与产科急症

FDA纳洛酮非处方药药品事实标签的消费者理解研究

FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone.
PubMed 文献 · N Engl J Med · 2020-01-01
一句话结论FDA模型纳洛酮非处方药标签的8项主要终点中6项达标,2项接近目标,FDA认为该标签足以用于非处方纳洛酮产品开发。

为评估消费者对纳洛酮非处方药标签关键语句的理解,FDA开发了模型药品事实标签并开展标签理解研究,对710名成人及青少年(含430名阿片类药物使用者及其亲友)进行个体结构化访谈。研究设定8项主要终点,每项预设80%至90%的目标阈值,通过比较95%精确置信区间下限进行评估。6项主要终点达到或超过阈值,如「检查疑似过量」点估计95.8%(阈值85%,95%CI 94.0至97.1)和「给予第一剂」点估计98.2%(阈值85%,95%CI 96.9至99.0);「立即拨打911」点估计90.3%(95%CI 87.9至92.4)接近90%目标;复合步骤「检查、给予并立即拨打911」点估计81.1%(阈值85%,95%CI 78.0至83.9)未达标。FDA认为该模型标签足以用于开发非处方纳洛酮产品。

要点

  • 710名成人及青少年(含430名阿片类药物使用者及其亲友)参与标签理解结构化访谈,评估FDA模型纳洛酮非处方药标签。
  • 8项主要终点中6项达到或超过预设阈值(80%至90%),「检查疑似过量」点估计95.8%(阈值85%,95%CI 94.0至97.1)。
  • 「给予第一剂」点估计98.2%(阈值85%,95%CI 96.9至99.0),达标。
  • 「立即拨打911」点估计90.3%(95%CI 87.9至92.4),接近90%目标阈值;复合步骤「检查、给予并立即拨打911」点估计81.1%(阈值85%,95%CI 78.0至83.9),未达标。
  • FDA认为该模型标签足以用于开发拟非处方销售的纳洛酮产品。

适用人群与场景

  • 710名成人及青少年,包括430名使用阿片类药物的成人及其家人和朋友。

诊断标准与关键阈值

  • 8项主要终点,每项预设目标阈值80%至90%,通过95%精确置信区间下限与阈值比较进行评估。

研究设计与关键结果

  • 标签理解研究:对710名成人及青少年进行个体结构化访谈,评估FDA模型纳洛酮非处方药药品事实标签的理解。
  • 「检查疑似过量」阈值85%,点估计95.8%(95%CI 94.0至97.1),达标。
  • 「给予第一剂」阈值85%,点估计98.2%(95%CI 96.9至99.0),达标。
  • 另4项主要终点95%置信区间下限范围为88.8%至94.0%,均达到或超过阈值。
  • 「立即拨打911」点估计90.3%(95%CI 87.9至92.4),接近90%目标阈值。
  • 复合步骤「检查、给予并立即拨打911」阈值85%,点估计81.1%(95%CI 78.0至83.9),未达标。

证据类型、等级与局限

  • 证据类型:标签理解研究(个体结构化访谈)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • FDA认为该模型标签足以用于开发拟非处方销售的纳洛酮产品。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The opioid crisis highlights the need to increase access to naloxone, possibly through regulatory approval for over-the-counter sales. To address industry-perceived barriers to such access, the Food and Drug Administration (FDA) developed a model drug facts label for such sales to assess whether consumers understood the key statements for safe and effective use.

METHODS: In this label-comprehension study, we conducted individual structured interviews with 710 adults and adolescents, including 430 adults who use opioids and their family and friends. Eight primary end points were developed to assess user comprehension of each of the key steps in the label. Each of these end points included a prespecified target threshold ranging from 80 to 90% that was evaluated through a comparison of the lower boundary of the 95% exact confidence interval.

RESULTS: The results for performance on six primary end points met or exceeded thresholds, including the steps "Check for a suspected overdose" (threshold, 85%; point estimate [PE], 95.8%; 95% confidence interval [CI], 94.0 to 97.1) and "Give the first dose" (threshold, 85%; PE, 98.2%; 95% CI, 96.9 to 99.0). The lower boundaries for four other primary end points ranged from 88.8 to 94.0%. One exception was comprehension of "Call 911 immediately," but this instruction closely approximated the target of 90% (PE, 90.3%; 95% CI, 87.9 to 92.4). Another exception was comprehension of the composite step of "Check, give, and call 911 immediately" (threshold, 85%; PE, 81.1%; 95% CI, 78.0 to 83.9).

CONCLUSIONS: Consumers met thresholds for sufficient understanding of six of eight components of the instructions in the drug facts label for naloxone use and came close on two others. Overall, the FDA found that the model label was adequate for use in the development of a naloxone product intended for over-the-counter sales.

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Cohen BR, Mahoney KM, Baro E, et al. FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone. N Engl J Med. 2020. PMID: 32459923. doi:10.1056/NEJMsa1912403

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。